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The purpose of this study was to assess characteristics, 
treatment outcomes and complications in patients with 
locally advanced or recurrent gynecological malignancies 
treated with interstitial brachytherapy using MUPIT. 
Materials and Methods: We performed a retrospective 
review of all patients with gynecological malignancies 
treated with MUPIT in a single institution between January 
2005 and May 2014. Cases without data or follow up were 
excluded. Information recorded were demographic and clinic 
characteristics, previous use of RT (external or BT), dose rate 
of interstitial BT, local control rate, late toxicity and 
mortality rate. Categorical variables are presented as 
frequencies and proportions, and continuous variables as the 
mean, median, and range. Local recurrence-free survival 
(LRFS) and overall survival (OS) after MUPIT treatment were 
estimated using the Kaplan-Meier method. 
Results: Forty six patients were identified. The median age 
was 64 years (range, 28 - 85). Cervical and endometrial 
cancers were the most common primary site, with 20 and 16 
cases respectively. The indications of interstitial BT were 
treatment of local recurrence (31), primary tumor (14) and 
metastases (1). Forty patients received external RT or BT 
before interstitial BT. High dose rate BT was used in 37 cases. 
Median LRFS was 76.2 months (CI 95% 61.6 - 90.7) and the 
median survival time was 82 months (CI 95% 67.5 - 96.5). 
There have been no cases of Grade IV late toxicity. Proctitis 
and pelvic pain were the most common grade III 
complications (4 patients). 
Conclusions: Interstitial BT using MUPIT applicator is an 
effective treatment which obtains high rates of local control 
despite the bad prognosis of pelvic recurrencies. Secondary 
effects are few, and manageable. 
   
EP-1267   
Defining a standard method for functional bone marrow 
sparing with IMRT for cervical cancer  
K. Morrison1, I. Zerizer2, R. Trouncer1, I. Murray2, K. Amin1, A. 
Taylor1 
1Royal Marsden Hospital, Radiotherapy, London, United 
Kingdom  
2Royal Marsden Hospital, Imaging, London, United Kingdom  
 
Purpose/Objective: Bone marrow sparing using intensity-
modulated radiotherapy (IMRT) could reduce haematological 
toxicity from radical chemoradiation for cervical carcinoma. 
One challenge is to determine the location of functioning 
bone marrow rather than attempt to spare the whole bony 
pelvis. On FDG-PET the areas of higher activity correlate with 
SUV values, and the scans used to stage disease could 
potentially be used to also identify functioning bone marrow. 
The aims of this study were to identify functioning pelvic 
bone marrow using FDG-PET, to analyse the pattern of 
distribution between patients and to develop guidelines for 
defining bone marrow as an organ at risk which can be 
applied to radiotherapy CT scans for all patients.  
Materials and Methods: The FDG-PET scans from 10 patients 
treated for cervical cancer were assessed. Structure sets 
consisting 6 absolute SUV thresholds (0.5,1.0, 1.5, 2.0, 2.5 
and 3.0) were created. The distribution of SUV activity within 
each pelvic subregion and the whole bony pelvis was 
analysed. The maximum SUV value within the bony pelvis 
(SUVmax) was defined as the highest level with a volume > 
1cc. Volumetric data for SUVMax, SUV >75%Max (SUV75) and 
SUV>50%Max (SUV50) were compared, measuring the 
contribution to each region and to the total activity.  
Results: The absolute SUV values within the pelvis varied 
between patients whereas relative values were more 
comparable. A reproducible pattern of distribution was 
evident in all patients using SUV75. The highest activity is 
seen within the lumbar spine, sacrum, posterior iliac alae and 
pubic bone contributing 86.67% total activity. For SUV75, the 
SUV range was 1.0 – 2.5 with a mean volume of 98.9cc (Range 
19.99 – 196.0cc, SD 50.3), which is 6.9% (range 1.7 – 12.9, SD 
3.2) of the mean total pelvic volume. 
Conclusions: There is a reproducible pattern of functional 
bone marrow on FDG-PET within the pelvis. Guidelines for 
contouring a standard avoidance structure on the planning CT 
scan have been generated which encompass the areas of 
highest activity. Bone marrow avoidance should be assessed 
further in dosimetric and clinical studies. 
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Purpose/Objective: To monitor changes in tumour 
microenvironment including hypoxia of cervix cancer patients 
undergoing chemoradiation with positron emission 
tomography and multiparametric 3T-magnetic resonance 
imaging (MP-PET/MRI) using T2-weighted, T1-weighted, 
dynamic-contrast-enhanced (DCE) MRI, diffusion-weighted 
imaging (DWI) and 18F-fluoromisonidazole 
(18F-FMISO). 
Materials and Methods: Seven patients underwent 18F-FMISO-
PET/CT and MP-MRI at baseline; 2 and 5 weeks(w) after 
treatment start and 3 months after treatment end. Data were 
registered, fused and analyzed using Mirada RTx software 
(Mirada Medical Ltd, Oxford,UK). Gross tumour volume (GTV) 
was contoured by an experienced radiation oncologist on 
PET/MRI data sets. The volume of GTV was analysed for size, 
EH-kinetics, diffusivity and 18F-FMISO-avidity using SUVmax 
and SUV-normalized to gluteal muscle uptake. At follow up, 
cervix was contoured, since all patients showed clinically 
complete remission. 
Results: Median GTV volume was 43.9cc at baseline, 22.4cc 
after 2w (20-25Gy) and 7.7cc after 5w (40-45Gy). Mean ADC 
values were 1.02x10-3mm2/sec increasing to 1.18x10-
3mm2/sec after 2w and to 1.27x10-3mm2/sec after 5w and 
were 1.37x10-3mm2/sec at 3 months. All GTVs showed mean 
initial-enhancement (IE) followed by a plateau with an 
increasing IE at 2w and 5w and wash-out at 5w. At follow-up, 
the mean IE was 120% followed by a persistent enhancement. 
The mean 18F-FMISO SUV-norm was 3.1 at baseline and 
decreased to 2.3 at 2w and 2.0 at 5w and follow-up. 
Conclusions: There are morphological and functional changes 
in tumor diffusion, perfusion and hypoxia during treatment 
which can be non-invasively monitored with MP-MRI/PET. The 
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magnitude of response is dependent on time points of 
evaluation. The predictive power of these changes on long 
term treatment outcome is object of ongoing prospective 
study. 
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Purpose/Objective: The scenario in cancer research is 
currently progressively moving on the analysis of established 
large database, realized by crossing and combining multiple 
data. These data must be analyzed by ad-hoc computer 
softwares to produce models that can predict the treatment 
outcomes in a reliable way. In order to make possible the 
integration and analysis of data from different cancer centers 
and cancer registries, to elaborate predictive models from 
large datasets there is the need of an 'ontology', a kind of 
dictionary that standardizes the medical terminologies. 
Materials and Methods: We defined the ontology evaluated 
by a multi-professional technical commission composed by a 
mathematician, an engineer, a doctor with experience in 
data storage, a programmer and a software expert. 
Results: More than 200 clinical, instrumental and imaging 
variables were cataloged and stored in three different levels. 
The first level (Registry Level) includes patient-related 
variables (age, sex, ethnicity, height, weight, etc.) that can 
be easily used for epidemiological analyzes. The second level 
(Procedure Level) includes data on the clinical presentation 
and pathology of the tumor, therapeutic procedures and their 
side effects. The third and final level (Research Level) will 
provide for the storage of data in advanced searches. In our 
ontology we preferably used concepts from existing and 
mature terminological systems (e.g. NCI Thesaurus, CTCAE, 
SNOMED-CT). We used field types as text, number, date, 
table, files. The chosen standard file formats were 'DICOM' 
for image and 'TXT files' for data treatment. The toxicity was 
stored with CTC4 scale and the RTOG scale (for back 
comparison with retrospective studies). 
Conclusions: A formal ontology is necessary to obtain a 
standardized and organized dataset. This allows to create a 
system to share and to analyze data from large multi-centers 
database. These data can be used to elaborate predictive 
models to tailored treatment in daily clinical practice.  
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Purpose/Objective: Descriptive analysis of high-risk 
neuroblastoma´s treated with volumetric modulated arc 
therapy (VMAT) based in 'SIOP-Europe 2011 high-risk 
neuroblastoma' guidelines. 
Materials and Methods: Based in International 
Neuroblastoma Staging System (INSS), we classify high-risk 
neuroblastoma those in stage 2, 3, 4 y 4S plus N-myc 
amplification, or stage 4 over one year-old. From september 
2010-2014 seventeen patients were treated with VMAT. 76.4% 
were boys and 23.6% girls, with a medium age of 37 months. 
N-myc amplification was positive in 47%. With INSS criteria, 
we noted:  
 
Stage (based in INSS) 
4 76.4%
3 11.8%
2 5.9% 
4S 5.9% 
Anatomical location 
Adrenal gland 64.7%
Abdominal 17.6%
Bilateral adrenal gland 5.8% 
Cervical 5.8% 
Thoraco-abdominal 5.8% 
 
After induction chemotherapy (COJEC), tumor exeresis and 
autologous blood marrow transplantation, all patients 
considered eligible for participation in this study were 
treated with VMAT (21 Gy maximum dose, fractioned over in 
14 sessions, 1,5 Gy each one) over the primary tumor area.  
Results: After medium folllow-up of 23 months (8-41), 41% 
are alive without tumor, 11.7% are alive with tumor, 23,5% 
have died because the tumor, 17.6% have died because an 
intercurrent cause, and 5.8% are dead by an unclearly 
cause.The radiotherapy tolerance was acceptable: 23.5% 
presented acute gastrointestinal toxicity grade 1-2 related to 
treatment. No chronicle toxicity has been noted.  
Conclusions: The N-myc amplification is clearly associated 
with major relapse risk and dead related with progression. 
This analysis revealed that VMAT in high-risk neuroblastoma´s 
treatment contributes to locoregional control with aceptable 
tolerance. There are no enough studies that compare VMAT 
with other techniques in high-risk neuroblastoma´s 
treatment. It is important the long follow-up of these 
patients to evaluate second neoplasms incidence, 
locorregional control and increase survival. 
   
EP-1271   
Development of focused microwave hyperthermia of 
pediatric brain cancer 
H. Dobsicek Trefna1, H.P. Kok2, P. Takook1, J. Gellermann3, 
B. Lannering4, K. Blomgren5, H. Crezee2, M. Persson1 
1Chalmers University of Technology, Signals and systems, 
Göteborg, Sweden  
2AMC Academic Medical Center, Radiotherapy, Amsterdam, 
The Netherlands  
3University Hospital Tuebingen, Radiation Oncology, 
Tuebingen, Germany  
